ORBi: Detailled Reference

Article (Scientific journals)

Glucotoxicité et lipotoxicité dans le diabète de type 2 : comment protéger la cellule β ?

SCHEEN, André

2020 • In Médecine des Maladies Métaboliques

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/253703

DOI
10.1016/j.mmm.2020.05.005

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2020 MMM Lipotoxicité.pdf

Publisher postprint (1.75 MB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Diabète de type 2; glucotoxicité; lipotoxicité; Hyperglycémie chronique

Abstract :

[fr] Un des objectifs majeurs, par ailleurs difficile à atteindre, dans la prise en charge du diabète de type 2 est de protéger la cellule b. Cette stratégie permettrait d'éviter ou retarder la perte structurelle et fonctionnelle progressive qui aboutit à un effondrement inéluctable de l'insulinosécrétion et, donc, à un échappement du contrôle glycémique. La glucotoxicité et la lipotoxicité jouent, de concert, un rôle dans ce processus, et les corriger devrait contribuer à se rapprocher de l'objectif, voire permettre de récupérer la partie réversible du déficit fonctionnel de la cellule b. Nous décrirons les approches non médicamenteuses et pharmacologiques susceptibles d'atténuer les phénomènes de glucotoxicité et de lipotoxicité chez les patients diabétiques de type 2. Récemment, certains espoirs ont été apportés par les agonistes des récepteurs du glucagon-like peptide-1 (GLP-1) et les inhibiteurs des cotransporteurs sodium-glucose de type 2 (SGLT2).
[en] One of the major goals, yet hard to be reached, in the management of type 2 diabetes (T2D) is to protect b-cell. This would avoid or retard the structural and functional progressive loss that leads to an inevitable exhaustion of insulin secretion and thereby a loss of glucose control. Both glucose toxicity and lipotoxicity play a role in this process so that the correction of these metabolic features should contribute to approach the objective, and even possibly restore the reversible part of the b-cell functional defect. We will describe the non-pharmacological and pharmacological approaches that may alleviate glucolipotoxicity in patients with T2D. Recently, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors rose some new hopes in this matter.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

SCHEEN, André ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques

Language :

French

Title :

Glucotoxicité et lipotoxicité dans le diabète de type 2 : comment protéger la cellule β ?

Alternative titles :

[en] Glucose toxicity and lipotoxicity in type 2 diabetes: How to protect β-cell?

Publication date :

2020

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Publisher :

Elsevier Masson, Paris, France

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 03 December 2020

Statistics

Number of views

139 (5 by ULiège)

Number of downloads

4 (3 by ULiège)

More statistics

Scopus citations^®

0

Scopus citations^®
without self-citations

0

OpenCitations

0

OpenAlex citations

0

Bibliography

DeFronzo, R.A., Diabetes 58 (2009), 773–795.
Scheen, A.J., Paquot, N., Le diabète de type 2 : voyage au cœur d'une maladie complexe. Rev Med Liege 67 (2012), 326–331.
Fonseca, V.A., Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32:Suppl. 2 (2009), S151–S156.
Ferrannini, E., Mari, A., β-cell function in type 2 diabetes. Metabolism 63 (2014), 1217–1227.
van Raalte, D.H., Verchere, C.B., Improving glycaemic control in type 2 diabetes: stimulate insulin secretion or provide beta cell rest?. Diabetes Obes Metab 19 (2017), 1205–1213.
Yki-Järvinen, H., Glucose toxicity. Endocr Rev 13 (1992), 415–431.
Rossetti, L., Giaccari, A., DeFronzo, R.A., Glucose toxicity. Diabetes Care 13 (1990), 610–630.
Cusi, K., The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diabetes Rep 10 (2010), 306–315.
Wajchenberg, B.L., ß-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28 (2007), 187–218.
Kaneto, H., Obata, A., Shimoda, M., et al. Promising diabetes therapy based on the molecular mechanism for glucose toxicity: usefulness of SGLT2 inhibitors as well as incretin-related drugs. Curr Med Chem 23 (2016), 3044–3051.
UK Prospective Diabetes Study Group, UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 44 (1995), 1249–1258 [Erratum in: Diabetes 1996;45:1655].
Halban, P.A., Polonsky, K.S., Bowden, D.W., et al. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 37 (2014), 1751–1758.
Scheen, A.J., Paquot, N., Lefèbvre, P.J., Glucotoxicité et lipotoxicité, deux complices impliqués dans le cercle vicieux du diabète de type 2. Rev Med Liege 54 (1999), 535–538.
Lytrivi, M., Castell, A.L., Poitout, V., Cnop, M., Recent insights into mechanisms of ß-cell lipo- and glucolipotoxicity in type 2 diabetes. J Mol Biol 432 (2020), 1514–1534.
Imai, Y., Cousins, R.S., Liu, S., et al. Connecting pancreatic islet lipid metabolism with insulin secretion and the development of type 2 diabetes. Ann N Y Acad Sci 1461 (2020), 53–72.
Ye, R., Onodera, T., Scherer, P.E., Lipotoxicity and ß-cell maintenance in obesity and type 2 diabetes. J Endocr Soc 3 (2019), 617–631.
Shimo, N., Matsuoka, T.A., Miyatsuka, T., et al. Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key ß-cell factors under diabetic conditions. Biochem Biophys Res Commun 467 (2015), 948–954.
Poitout, V., Robertson, R.P., Glucolipotoxicity: fuel excess and beta cell dysfunction. Endocr Rev 29 (2008), 351–366.
Del Prato, S., Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 26 (2009), 1185–1192.
Meex, R.C., Blaak, E.E., van Loon, L.J., Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes. Obes Rev 20 (2019), 1205–1217.
Burgos-Morón, E., Abad-Jiménez, Z., Martínez de Marañón, A., et al. Relationship between oxidative stress, ER stress, and inflammation in type 2 diabetes: the battle continues. J Clin Med, 8, 2019, 1385.
Marchetti, P., Lupi, R., Del Guerra, S., et al. Goals of treatment for type 2 diabetes: ß-cell preservation for glycemic control. Diabetes Care 32:Suppl. 2 (2009), S178–S183.
Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Diabetes Prevention Program Research Group, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
Kitabchi, A.E., Temprosa, M., Knowler, W.C., Diabetes Prevention Program Research Group, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 54 (2005), 2404–2414.
DeFronzo, R.A., Tripathy, D., Schwenke, D.C., ACT Study NOW, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364 (2011), 1104–1115.
Defronzo, R.A., Tripathy, D., Schwenke, D.C., ACT Study NOW, et al. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes 62 (2013), 3920–3926.
Scheen, A.J., Luyckx, F.H., Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 16 (2002), 703–716.
Montgomery, M.K., De Nardo, W., Watt, M.J., Impact of lipotoxicity on tissue “cross talk” and metabolic regulation. Physiology (Bethesda) 34 (2019), 134–149.
Guess, N.D., Dietary interventions for the prevention of type 2 diabetes in high-risk groups: current state of evidence and future research needs. Nutrients, 10, 2018, 1245.
Stinkens, R., Goossens, G.H., Jocken, J.W., Blaak, E.E., Targeting fatty acid metabolism to improve glucose metabolism. Obes Rev 16 (2015), 715–757.
Scheen, A.J., De Flines, J., De Roover, A., et al. Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives. Diabetes Metab 35 (2009), 537–543.
Sista, F., Abruzzese, V., Clementi, M., et al. Resolution of type 2 diabetes after sleeve gastrectomy: a 2-step hypothesis. Surg Obes Relat Dis 14 (2018), 284–290.
Holst, J.J., Madsbad, S., Bojsen-Møller, K.N., et al. Mechanisms in bariatric surgery: gut hormones, diabetes resolution, and weight loss. Surg Obes Relat Dis 14 (2018), 708–714.
Ritz, P., Vaurs, C., Barigou, M., Hanaire, H., Hypoglycaemia after gastric bypass: mechanisms and treatment. Diabetes Obes Metab 18 (2016), 217–223.
Scheen, A.J., De Flines, J., Rorive, M., et al. La chirurgie métabolique, vers une (r)évolution de la chirurgie bariatrique ?. Rev Med Liege 66 (2011), 183–190.
Nannipieri, M., Baldi, S., Mari, A., et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab 98 (2013), 4391–4399.
Chen, X., Zhang, J., Zhou, Z., Targeting islets: metabolic surgery is more than a bariatric surgery. Obes Surg 29 (2019), 3001–3009.
Andreelli, F., Amouyal, C., Magnan, C., Mithieux, G., What can bariatric surgery teach us about the pathophysiology of type 2 diabetes?. Diabetes Metab 35 (2009), 499–507.
Rebelos, E., Seghieri, M., Natali, A., et al. Influence of endogenous NEFA on beta cell function in humans. Diabetologia 58 (2015), 2344–2351.
Wallemacq, C., Effet diabétogène des statines : balance bénéfices–risques. Rev Med Suisse 15 (2019), 1454–1457.
Belfort, R., Berria, R., Cornell, J., Cusi, K., Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 95 (2010), 829–836.
Goldberg, R.B., Jacobson, T.A., Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 83 (2008), 470–478.
Hansen, M., Scheltema, M.J., Sonne, D.P., et al. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. Diabetes Obes Metab 18 (2016), 571–580 [Erratum in: Diabetes Obes Metab 2018;20:759].
Fonseca, V.A., Handelsman, Y., Staels, B., Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab 12 (2010), 384–392.
Qvigstad, E., Mostad, I.L., Bjerve, K.S., Grill, V.E., Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects. Am J Physiol Endocrinol Metab 284 (2003), E129–E137.
Cusi, K., Kashyap, S., Gastaldelli, A., et al. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab 292 (2007), E1775–E1781.
Merovci, A., Abdul-Ghani, M., Mari, A., et al. Effect of dapagliflozin with and without acipimox on insulin sensitivity and insulin secretion in T2DM males. J Clin Endocrinol Metab 101 (2016), 1249–1256.
Mirouze, J., Insulin treatment: a non-stop revolution. Diabetologia 25 (1983), 209–221.
Retnakaran, R., Zinman, B., Short-term intensified insulin treatment in type 2 diabetes: long-term effects on ß-cell function. Diabetes Obes Metab 14:Suppl. 3 (2012), 161–166.
Liu, L., Yang, S., Liu, J., et al. Fasting plasma glucose indicates reversibility of the acute insulin response after short-term intensive insulin therapy in patients with various duration of type 2 diabetes. J Diabetes Res, 2018, 2018 [9423965].
Walter, H., Lübben, G., Potential role of oral thiazolidinedione therapy in preserving ß-cell function in type 2 diabetes mellitus. Drugs 65 (2005), 1–13.
Kahn, S.E., Haffner, S.M., Heise, M.A., ADOPT Study Group, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006), 2427–2443 [Erratum in: N Engl J Med 2007;356:1387–8].
Kahn, S.E., Lachin, J.M., Zinman, B., ADOPT Study Group, et al. Effects of rosiglitazone, glyburide, and metformin on ß-cell function and insulin sensitivity in ADOPT. Diabetes 60 (2011), 1552–1560.
Drucker, D.J., Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27 (2018), 740–756.
Fontés, G., Hagman, D.K., Latour, M.G., et al. Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity. Diabetes Res Clin Pract 87 (2010), 322–328.
Retnakaran, R., Kramer, C.K., Choi, H., et al. Liraglutide and the preservation of pancreatic ß-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 37 (2014), 3270–3278.
Bunck, M.C., Diamant, M., Cornér, A., et al. One-year treatment with exenatide improves ß-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32 (2009), 762–768.
Bunck, M.C., Cornér, A., Eliasson, B., et al. Effects of exenatide on measures of ß-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34 (2011), 2041–2047.
Abdul-Ghani, M.A., Puckett, C., Triplitt, C., et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 17 (2015), 268–275.
Rossetti, L., Shulman, G.I., Zawalich, W., DeFronzo, R.A., Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80 (1987), 1037–1044.
Scheen, A.J., Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2. Med Mal Metab 12 (2018), 22–30.
Scheen, A.J., Paquot, N., Metabolic effects of SGLT2 inhibitors beyond increased glucosuria: a review of clinical evidence. Diabetes Metab 40:Suppl. 1 (2014), S4–S11.
Kaneto, H., Obata, A., Kimura, T., et al. Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic ß-cell function and reduction of insulin resistance. J Diabetes 9 (2017), 219–225.
Bonnet, F., Scheen, A.J., Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetic complications and cardiovascular disease. Diabetes Metab 44 (2018), 457–464.
Ahn, C.H., Oh, T.J., Kwak, S.H., Cho, Y.M., Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic ß-cells in people with type 2 diabetes. Diabetes Obes Metab 20 (2018), 370–377.
Svendsen, B., Larsen, O., Gabe, M.B., et al. Insulin secretion depends on intra-islet glucagon signaling. Cell Rep, 25, 2018 [1127–34 e2].
Wang, Q., Liang, X., Wang, S., Intra-islet glucagon secretion and action in the regulation of glucose homeostasis. Front Physiol, 3, 2012, 485.
Nagai, Y., Ohta, A., Sada, Y., et al. Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes. Expert Opin Pharmacother 18 (2017), 13–17.
Polidori, D., Mari, A., Ferrannini, E., Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 57 (2014), 891–901.
Kimura, T., Obata, A., Shimoda, M., et al. Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic ß-cells in db/db mice: the earlier and longer, the better. Diabetes Obes Metab 20 (2018), 2442–2457.
Cheng, S.T., Chen, L., Li, S.Y., et al. The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic ß-cell mass and glucose homeostasis in type 1 diabetes. PLoS One, 11, 2016, e0147391.
Shirakawa, J., Tajima, K., Okuyama, T., et al. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. Diabetologia 63 (2020), 577–587.

Similar publications